Medincell SA
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is… Read more
Medincell SA (MEDCL) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.465x
Based on the latest financial reports, Medincell SA (MEDCL) has a cash flow conversion efficiency ratio of 0.465x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-14.25 Million) by net assets (€-30.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medincell SA - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Medincell SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Medincell SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medincell SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Lihexing Co. Ltd.
SHE:301013
|
-0.030x |
|
Shaanxi Heimao Coking Co Ltd
SHG:601015
|
0.086x |
|
Molson Coors Canada Inc
TO:TPX-B
|
0.051x |
|
OKEANIS ECO TANK. DL-001
F:7OK
|
N/A |
|
FirstSun Capital Bancorp Common Stock
OTCQX:FSUN
|
0.044x |
|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
-0.075x |
|
Shandong Jincheng Pharmaceutical and Chemical Co Ltd
SHE:300233
|
0.021x |
|
Cosonic Intelligent Tech Co Ltd
SHE:300793
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Medincell SA (2016–2025)
The table below shows the annual cash flow conversion efficiency of Medincell SA from 2016 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | €-16.37 Million | €19.46 Million | -1.189x | -507.24% |
| 2024-03-31 | €-40.82 Million | €-11.92 Million | 0.292x | -41.20% |
| 2023-03-31 | €-42.29 Million | €-21.00 Million | 0.497x | -68.91% |
| 2022-03-31 | €-13.37 Million | €-21.36 Million | 1.598x | +217.37% |
| 2021-03-31 | €8.92 Million | €-12.14 Million | -1.361x | -273.23% |
| 2020-03-31 | €-15.96 Million | €-12.54 Million | 0.786x | +130.79% |
| 2019-03-31 | €6.24 Million | €-15.93 Million | -2.552x | -652.58% |
| 2018-03-31 | €-11.75 Million | €-5.43 Million | 0.462x | -68.86% |
| 2017-03-31 | €-2.29 Million | €-3.39 Million | 1.483x | +2787.40% |
| 2016-03-31 | €1.32 Million | €68.00K | 0.051x | -- |